Bio: Dr. med. Uwe Marx is Honorary Professor for Medical Biotechnology at the Technical University of Berlin, Germany. He has been a pioneer in the development of multi-organ chips since 2007. Dr. Marx has published more than 200 peer-reviewed papers and several book chapters and hosted the three stakeholder CAAT workshops of the MPS community in 2015, 2019 and 2023 as well as the 2nd MPS World Summit in Berlin in June 2023. He developed the theoretical background of the organismoid theory (Marx et al, Frontiers in Medicine 2021, doi:10.3389/fmed.2021.728866). Several hundred patents granted worldwide protect the results of his development work. He is a serial German entrepreneur and co-founder of ProBioGen AG, Berlin, Germany and VITA 34, Leipzig, Germany. Dr. Marx is the recipient of the prestigious 2021 Russell & Burch Award of the Humane Society of the United States of America. He is the founder and CSO of TissUse GmbH, a 2010 spin-off from the Technical University of Berlin, which commercializes the HUMIMIC® technology platform.

Abstract: Over the past decade a variety of human organoid models have been established to mimic single organ (patho) physiology in standard cell culture. However, these organoids lack physiological perfusion of nutrients and inter-organ crosstalk to better mimic human biology in vitro. A wide range of microfluidic microphysiological systems have been developed to fill this gap (Marx et al., ALTEX, 2025, doi:10.14573/altex.2410112). They are about to revolutionise basic research in human biology, the development of curative therapies and the precision of personalised medicine. The integration of human organoids into single- and multi-organ chips led to advanced tools for toxicity testing of chemicals, drugs, biologics and advanced therapies. The presentation will showcase advanced human single- and multi-organ chip assays for ADME-profiling, toxicity testing and disease modelling. Finally, it will highlight how stem cell technologies, organoid differentiation platforms and MPS-based computational modelling are converging to enable automated large-scale operation of multi-organ chips reflecting patient’s systemic (patho) physiology for on-chip clinical trials in the future.